Video

Dr. Branagan on Tandem Transplants in Multiple Myeloma

Andrew Branagan, MD, discusses the research tandem transplants in patients with high-risk multiple myeloma.

Andrew Branagan, MD, a medical oncologist in the Center for Multiple Myeloma at Mass General Cancer Center in Massachusetts General Hospital, discusses the research tandem transplants in patients with high-risk multiple myeloma.

Tandem transplants, meaning 2 back-to-back transplants, are being investigated in multiple myeloma treatment, explains Branagan. Tandem transplants are not a new concept and have occurred in the past, according to Branagan.

The European Society for Blood and Marrow Transplantation conducted a promising study showing that doing tandem transplant was beneficial in high-risk patients with multiple myeloma; however, these results were not validated in the United States, says Branagan. Tandem transplants, according to Branagan, are not going to change practice yet, but it is a consideration for a high-risk patient to do 2 transplants back-to-back.

Related Videos
J. Bradley Elder, MD
Rimas V. Lukas, MD
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Diane Reidy-Lagunes, MD, vice chair, Oncology Operations, Regional Care Network, Memorial Sloan Kettering Cancer Center
Shubham Pant, MD, MBBS
Kevin Kalinsky, MD, MS, professor, Department of Hematology and Medical Oncology, director, Division of Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine; Louisa and Rand Glenn Family Chair in Breast Cancer Research, director, Glenn Family Breast Center, director, Breast Medical Oncology, Winship Cancer Institute of Emory University
Brett L. Ecker, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Yelena Y. Janjigian, MD, chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center
Howard S. Hochster, MD, FACP,